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Despite radical treatment, many men with prostate cancer will develop 
recurrence of their disease. In an exciting era of new therapies for prostate 
cancer in general, we focus on how these will specifically benefit those men 
with recurrent disease. We consider salvage treatments aimed at those with 
local recurrence confined to the prostate gland, therapies for those presenting 
with metastatic recurrence and the approach to men presenting with a rising 
PSA but no demonstrable disease (M0). In general, men with recurrent 
disease are often under-represented in randomised clinical trials. 
Subsequently, evidence to guide treatment for these men is often lacking and 
this needs to be addressed in order to improve and better define our approach 
to this problem in the future.  
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Emerging treatments for recurrent prostate cancer 
 
Observational studies have shown that in 30% of men radically treated for 
localised prostate cancer with, for example, radical prostatectomy or external 
beam radiotherapy, this primary therapeutic modality will fail.[1] The most 
suitable treatment will depend on the type of recurrence and the nature of 
prior interventions.  
 
Patterns of recurrence 
 
Biochemical recurrence  
For many men the first indication of recurrence will be a rising serum prostate 
specific antigen (PSA) referred to as ‘biochemical recurrence’ (BCR). BCR 
following radical prostatectomy (RP) is defined as any detectable PSA level 
following surgery and has been reported to occur in up to 35% of patients [2]. 
The exact cut-off level used to define failure for trial purposes has varied from 
>0.4ng/mL, > 0.2ng/mL or even lower levels with the use of contemporary 
high-sensitivity PSA assays.  
  
PSA levels after EBRT may never become undetectable and may “bounce” in 
the months following radiation. ‘Bounce’ is a benign phenomenon that occurs 
as a result of PSA production by recovering normal tissue in the prostate 
gland. In 2006 the American Society for Therapeutic Radiology and Oncology 
(ASTRO) re-defined criteria for BCR following EBRT as a rise by 2ng/mL or 
more above the nadir PSA.[3] This definition replaced the previous ASTRO 
definition of a rising PSA over three measurements.[4] BCR rates of up to 




This refers to demonstrable distant metastases outside the prostate gland on 
imaging studies, with or without a PSA rise.  
 
Investigation of recurrent disease 
 
Ultrasound and biopsy is the standard tool to diagnose local recurrence. 
However, this is an invasive procedure, with risks of infection and sampling 
error. Furthermore, results are often indeterminate in the recurrent prostate 
cancer setting, particularly in the initial 36 months following radiotherapy.[5] 
Multiparametric MRI (MP-MRI) combines anatomical and biological 
information and is a general term that covers the use of techniques such as 
dynamic contrast enhancement (DCE), diffusion weighted imaging and 
spectroscopy. Roy and colleagues retrospectively compared the effectiveness 
of all three of these modalities in diagnosing recurrent disease (confirmed on 
biopsy) in the post RP (28 patients) and post EBRT (32 patients) settings. 
Post RP the sensitivity was highest for T2 weighted MRI imaging with DCE 
(97%) followed by DCE alone (94%) and it was highest for T2WI plus DWI 
and DCEI (100%) in the post-EBRT setting. [6] [7] MR/ultrasound fusion 
guided biopsy has been shown to be superior in picking up high grade 
prostate cancers compared to standard sextant biopsy with ultrasound [6], but 
its utility in detecting recurrent disease remains uncertain.  
 
Metastatic disease can also be difficult to demonstrate using conventional 
imaging. CT and technetium-99m bone scanning are often not sensitive 
enough to pick up low volume disease at the time of BCR.[7] Conventional 
PET-CT using fluorodeoxyglucose is suboptimal in this context due to modest 
glucose consumption by prostate cancer cells, the fact that uptake in recurrent 
tumour is similar to that in postoperative scarring or benign tissue and its 
excretion via the bladder obscuring the view of the prostate / prostatic bed. 
PET-CT using 11C-choline, a tracer which targets components of the 
phospholipids in the prostate cell membrane, has shown better results  [8][9] 
and novel PET radiotracers such as those that target prostate-specific 
membrane antigen (PSMA) are being investigated in the hope that these will 
show greater sensitivity and specificity for the detection of prostate cancer 
recurrences. [10, 11] [12] Sodium fluoride F-18 imaging has also shown 
promising results, specifically for the identification of bone metastases.[13] 
 
 
Local salvage therapy 
 
Although deferred ADT is the most commonly used therapy for BCR, local 
treatment options that are increasingly employed (up to 72% of those with 
BCR following EBRT).[14] These can offer a second chance of cure to such 
men. They include salvage prostatectomy (SRP), cryotherapy (CA), high 
intensity focused ultrasound (HIFU) and photodynamic therapy (PDT). 
Predictors that may help to select patients who will derive most benefit from 
these therapies include low risk disease at time of original diagnosis, time to 
PSA failure and longer PSA doubling times (PSADT) at the time of BCR.[15] 
Lack of consistency in trials with regards to the use of ADT and in the 
definition of failure following salvage treatment means that indirect 
comparison of the efficacy of these novel therapies is challenging.  
 
Salvage radical prostatectomy (SRP) following EBRT 
Only a small proportion of men with BCR following EBRT will have SRP (0.9-
2%) [16] and good quality prospective trials assessing outcomes are lacking. 
A retrospective, multi-centre cohort analysis of 404 men with recurrent 
prostate cancer after EBRT who underwent SRP between 1985-2009 
reported ten year biochemical disease free (bDFS) and cancer-specific 
survival (CSS) rates of 37% and 83% respectively. [17] The median age of 
patients was 65 and the median pre-SRP PSA was 4.5 (IQR 2.5-7.4). 
Multivariate analysis identified a more favourable group (93 men; 
approximately 30% of the cohort) who had pre-SRP Gleason score less than 
or equal to 7 and pre-SRP PSA less than or equal to 4ng/mL and showed that 
they had a BCR free probability of 64% (95% CI 52-74%) at 5 years and 51% 
(95% CI 35-64%) at 10 years. However, these were uncontrolled data in a 
likely highly selected population, so their applicability to the clinical setting 
remains uncertain. More recently, a systematic review [18] showed that pre-
SRP PSA and prostate biopsy Gleason score were the strongest prognostic 
factors for progression free survival and CSS following SRP. A recent 
systematic review highlighted that BCR-free survival rates are significantly 
lower in trials that had longer follow up times (>40 months) indicating the time-
dependent nature of BCR-free survival as an outcome measure. [16] Case 
series have described the use of laparoscopic and robotic surgery and overall 
trends suggest that newer surgical techniques are helping to decrease the 
morbidity associated with SRP.[19] However morbidity following salvage 
surgery remains significantly higher compared to primary prostatectomy. In 
one report, the 90-day major surgical complication rate was 47% versus 5% in 
the primary prostatectomy population. [20] 
 
Minimally invasive salvage therapy following EBRT 
These treatments have been reported only in case series, it having proven 
difficult to recruit patients to trials with a placebo or ADT-only control arm. [21]  
A retrospective, non-randomised comparison of salvage CA (56 patients) with 
SRP (42 patients) showed that SRP was associated with significantly better 
rates of biochemical disease free survival (bDFC) and overall survival (OS) (at 
5 years OS 85% for salvage cryotherapy versus 95% for SRP, p=0.001) but 
there was no difference in disease specific survival (DSS).[22] Variations in 
baseline characteristics between the two groups in this study may explain at 
least some of the differences in outcome. Retrospective analysis shows that 
patients with low risk disease at initial diagnosis or pre-salvage PSA less than 
5ng/mL had 3-year and 10-year bDFS rates of 73% and 64% respectively but 
those with high risk disease or pre-salvage PSA over 5ng/mL had rates of 
11% and 6.7%.[23, 24] Focal cryotherapy has been explored in the COLD 
database which reports 5-year bDFS of 46.5% with similar toxicity to whole 
gland CA.[25] Complication rates for CA include urinary retention (6.6-12%), 
incontinence (5.5-13%), recto-urethral fistula (1-3.3%) and erectile dysfunction 
(ED) in up to 80-90% of men.[23, 25, 26] 
 
Case series describing the use of HIFU in the salvage setting have included 
heterogeneous populations with short follow up times.[27] A single institution 
review of 290 patients treated with HIFU for biopsy proven local relapse 
following EBRT reported 80% CSS rate at 7 years. As with CA, it is evident 
that HIFU should be used with caution in men with high risk features. In this 
study, 5-year progression free survival (PFS) rate was inversely related to 
pre-EBRT d’Amico risk score and was 45% (95% CI 32-63%) in the low risk 
and 21% (95% CI 13.6-32%) in the high risk group.[28] Murat and colleagues 
showed a similar difference in three-year survival rates between high and low 
risk groups.[29] Complications included rectal fistula in 2-16% [28, 30], urinary 
incontinence in up to 50% [29], pubic bone osteitis in 2.8% [28] and bladder 
neck obstruction requiring TURP in up to 38% of patients.[27]  
 
Finally, PDT uses intravenous photosensitising drugs followed by a focal light 
treatment given via optical fibres into the prostate gland. Phase I/II trials are 
on going to find the optimal doses of both drug and light required to give the 
best anti-tumour effect.[31] There are no trials reporting efficacy data. 
 
These newer techniques may be suitable for men with low risk disease who 
do not want or are not suitable for major salvage surgery however, toxicity 
profiles of these treatments are not clearly superior to SRP.  
 Salvage EBRT following primary RP 
Retrospective multivariate analyses have shown that salvage EBRT was 
associated with decreased cancer specific mortality [32]and all cause 
mortality [33] for patients who have BCR following primary treatment with RP. 
Trock and colleagues [32]found that the increase in prostate cancer specific 
survival (HR 0.32 (CI 0.91-0.54; p<0.001) was limited to those men with a 
PSADT of less than 6 months, those who received SRT within 2 years of BCR 
and those patients whose PSA had become undetectable at some stage post 
RP. For men who underwent SRT their median age was 58.3 years, average 
PSA pre-op was 8.3 and PSA pre-SRT was 0.7. There was a difference in 
prognostic factors between SRT, SRT plus HT and no SRT groups but no 
group overall had a worse prognostic profile. Fewer men undergoing SRT had 
lymph node involvement compared to those not undergoing SRT but CSS 
was still significant after analysis was repeated to exclude those with LN 
metastases. Choueiri and colleagues [33]reported that those in their cohort 
who underwent salvage therapies were more likely to have Gleason 8-10 
disease, T3b and above and PSADT <6 months. Details of patient co-
morbidities were not reported and may be an important confounder for all 
cause mortality in this group. A larger study (n=2657) that retrospectively 
looked at the benefits of SRT for 865 men who had BCR following RP found 
that they had lower risk of local recurrence and metastatic progression but 
there was no effect on overall survival compared to ADT alone. Specifically, 
improved survival was not apparent among patients with PSADT < 6months. 
Stephenson and colleagues have constructed a nomogram to predict which 
men will benefit most from salvage EBRT [34]. They show that factors such as 
pre-treatment PSA, positive surgical margins and seminal vesicle involvement 
adversely affected 6-year bDFS after SRT [35].  
 
 
Importantly, it has also been reported that using a different approach and 
giving radiotherapy adjuvantly for high-risk patients following RP improves 
biochemical progression free survival compared to observation.[36-38] 
Debate is on going surrounding which approach is better and head to head 
comparison trials to investigate this are under way (GETUG 17 
(NCT00667069), RAVES (NCT00860652) and RADICALS (NCT00541047)).  
 
Salvage EBRT plus hormone therapy 
Recently, the results of a phase III randomised trial have reported a significant 
improvement in 5-year PFS (72% versus 62%) for patients with BCR following 
RP treated with radiotherapy plus ADT versus radiotherapy alone.[39] There 
was no OS benefit but there were only 11 deaths in the whole group indicating 
that longer follow up times are needed to assess OS. RTOG 96-01 compared 
salvage RT to salvage RT plus two years of bicalutamide 150mg and reported 
improved failure free survival. RTOG 0534 (NCT00567580) will assess the 
benefit of adding short term ADT to SRT with or without extended 
radiotherapy fields to include lymph node beds. STREAM NCT02057939 will 
investigate if adding enzalutamide to ADT can improve outcomes further.  
 
Systemic therapy in recurrent prostate cancer 
Non-castrate M0 disease 
For many men with BCR but M0 disease, local salvage therapy is 
inappropriate because of a high clinical suspicion of distant micro-metastases. 
In this situation the standard of care is ADT. It is not clear if ADT should be 
used at the time of BCR or deferred until a “threshold” PSA or M1 disease is 
reached. Retrospective analysis of 1352 patients with PSA rise after RP 
showed no significant difference in OS or CSS for either approach.[40] The 
TROG 03.6 (TOAD) trial, which compared immediate (n= 142) with deferred 
ADT (n=151) in men with rising PSA with or without prior radical treatment or 
in those with asymptomatic disease at diagnosis who are unsuitable for 
curative treatment. 89 (58.9%) patients in the delayed arm were eventually 
treated with ADT at a median time of 18.7 months. It closed without full 
accrual but early results have shown that there was a non-statistically 
significant decrease in death from all causes (HR 0.54, (95% confidence 
interval (CI) 0.27,1.06, p = 0.07) and prostate specific death (HR 0.50 CI 
0.17,1.51, p = 0.22) in patients undergoing early ADT. Not surprisingly, in this 
trial there was a greater burden of toxicity among those patients randomized 
to receive early ADT.[41] 
 
Combining chemotherapy with initial ADT in patients with BCR but M0 
disease has been investigated in an uncontrolled phase II trial (n=62) which 
suggested this might improve outcomes. [42] The STAMPEDE trial has 
recently reported statistically and clinically significant improvements when 
docetaxel was added at the time of initiation of ADT in men with high risk 
locally advanced or metastatic hormone sensitive prostate cancer. At the first 
analysis however there was no significant survival benefit for the subgroup of 
patients without metastatic disease (39% of the total group), although there 
was a significant delay in time to recurrence. Men with BCR following radical 
treatment were included in this trial, but constituted less than 6% of the total 
group and so the use early use of docetaxel in this specific setting remains 
uncertain.[43]  
  
Non-castrate metastatic (M1) recurrence following local therapy  
The standard of care for treatment of metastatic disease is ADT. A recent 
Cochrane review reported significantly poorer OS when non-steroidal anti-
androgens were used alone compared with castration (HR 1.34, 95% CI 
1.14–1.57, 2103 participants), and so castration therapy remains the 
treatment of choice in this setting.[44]  
 
There has been increasing interest in additional therapies to ADT at this point 
of hormone sensitive disease rather than waiting for the disease to become 
castrate refractory. The “CHAARTED” trial reported a 13.6 month median OS 
benefit using upfront docetaxel with ADT compared to ADT alone in men with 
hormone naïve metastatic prostate cancer. In a pre-planned subgroup 
analysis, patients with high volume metastatic disease (visceral disease 
and/or 4 or more bone metastases including at least one extra-axial 
metastasis) had a 17 month improvement in median OS (40% reduction in 
risk of death). With a median follow up of 29 months there were insufficient 
events to demonstrate a significant benefit in the subgroup with low volume 
disease.  27% of patients had prior radical treatment and the overall benefits 
of the trial were maintained in this subgroup although the confidence intervals 
remain wide at the first analysis. [45] These data were tempered by 
contradictory results from the GETUG-15 trial which did not show a significant 
difference in OS (median 58.9 months in ADT plus docetaxel group (n=193, 
CI 50.8-69.1) and 54.2 months (n=192, CI 42.2-not reached) in the ADT alone 
group (HR 1.01, CI 0.75-1.36, p=0.955)). This trial included 272 patients with 
metastatic disease at diagnosis and 108 who had received prior radical 
treatment.[46] Most recently, the STAMPEDE trial reported a significant OS 
benefit for the addition of docetaxel to initial ADT (median survival 77 months 
versus 67 months for ADT alone; hazard radio 0.76 (95% CI 0.63, 
0.91;p=0.003)) in men with metastatic or locally advanced disease.[43]  
 
In summary, despite some conflicting results, it seems clear that the addition 
of docetaxel at the point of initial ADT results in improved OS for men 
presenting with metastatic disease at diagnosis. These trials only included 
small numbers of patients failing with metastatic disease after previous radical 
treatment, and so there remains uncertainty about the value of adding 
chemotherapy for these patients. 
 
Recurrent disease when on adjuvant hormones (Castrate Resistant 
Prostate Cancer) (M1 and M0) 
 
M1 versus M0 disease 
There have recently been several significant advances in the treatment of 
mCRPC and these have been reviewed elsewhere. [47] However, for the 
subgroup of men with M0 castration resistant disease there remains high 
unmet need. These men are at high risk of developing metastases and 
subsequent death from prostate cancer, but there are currently no licensed 
treatments which prevent or delay stage progression. In particular these 
patients were not included in the pivotal trials of docetaxel, abiraterone or 
enzalutamide and there are no data to support their use in this setting. There 
are two on-going trials of note: The PROSPER trial  (NCT02003924) is a 
placebo-controlled trial of enzalutamide and the SPARTAN trial 
(NCT01946204) explores the role of the novel, highly potent androgen 
receptor antagonist ARN-509. Both trials have a primary endpoint of distant 
metastasis free survival and continue to accrue patients. 
 
Bone therapies for recurrent CRPC (M1 and M0) 
Zoledronic acid (ZA) and denosumab have established roles in preventing 
skeletal related complications in men with CRPC and bone metastases.[46-
48] Neither agent has provided survival benefit. The STAMPEDE trial failed to 
show a survival benefit from adding ZA to ADT alone (HR 0.93, 95% CI 
0.79,1.11; p=0.437) or to ADT plus docetaxel in men with locally advanced or 
metastatic prostate cancer. Radioisotope treatment using radium-223 has 
shown improvement in median OS in men with mCRPC.  The specific role of 
all of these therapies in recurrent disease remains the subject of investigation. 
[48]  
 
The role of bone targetd therapy in M0 disease remains controversial.  A large 
randomized phase III trial of denosumab did show a 4.2 month delay in time 
to bone metastasis in men with high risk M0 CRPC, but there was no 
improvement in OS and the drug is not licensed in this setting.[49] 
 
Immunotherapy for CRPC (M1 and M0) 
 
Sipuleucel-T has been reported to extend median and 3-year survival  in men 
with mCRPC. [50] A retrospective, unplanned subgroup analysis suggested 
that men with low PSA at trial entry had a much greater survival gain than 
those with high PSA suggesting that it could be useful at the time of early 
metastatic disease relapse after radical treatment. The phase III PROTECT 
trial showed that Sipuleucel-T immunotherapy prolonged PSADT when added 
to ADT to treat men with BCR after primary prostatectomy (M0). The study did 
not meet its primary objective of extending time to biochemical failure or the 
secondary objective of improving OS although extended follow up may yet 
prove clinical benefit in this setting. [51]   
 
Other immune therapies including the vaccine therapy PROSTVAC-TRICOM 
and the immune checkpoint inhibitor ipilimumab have shown early signs of 
clinical benefit in CRPC and remain in clinical development in mCRPC. [52] 
[53]  
 
Overall, immunotherapies may be more effective if given relatively early in the 
course of the disease [53]rather than after exhausting all other therapies. 
Hence they may be a promising approach in men with recurrent prostate 




Finally, Robinson and colleagues have recently described abnormalities at the 
genetic level in bone or soft tissue tumour biopsies from 150 men with CRPC. 
[55] 89% had a potentially “actionable” genetic mutation such as an alteration 
in the androgen receptor gene (62.7%). The treatments available to take 
advantage of this genetic testing are sparse and this personalised approach is 
still very much in its infancy and in the realm of clinical trials for prostate 
cancer. The aim for the future will be to offer targeted treatment against 
aberrations in the genetic profile of a man’s prostate cancer in the hope of 
increasing efficacy and specificity of therapeutic agents and decreasing the 





The pattern and distribution of prostate cancer is changing. At present, a 
significant proportion of the men who die from prostate cancer do so having 
presented with advanced disease and, thus, have not received prior radical 
treatment. Through improved diagnosis and screening, more men are 
presenting with organ-confined disease and undergoing radical treatments. In 
addition, as life expectancy continues to increase, we can expect more of 
these men to develop problems associated with recurrent disease. Thus it is 
likely that, in the future, the problem of recurrent prostate cancer will become 
a significant burden. Although the concept of local salvage therapy is well 
established, conventional salvage therapies can be associated with significant 
morbidity and evidence to support novel interventions is still relatively poor. 
Despite major steps forwards in our understanding of systemic therapies in 
advanced prostate cancer, most of the trials which have been undertaken 
have failed to specifically address the needs of men with recurrent cancers 
and there is a need to better understand their application to this group of men. 
 
 
Executive summary (Not included in word count) 
 
Patterns of recurrence  
- Biochemical: Any rise in PSA after prostatectomy and rise of 2ng/dL over 
nadir after EBRT. Metastatic refers to demonstrable distant disease.  
Local salvage treatments  
- CA, HIFU and PDT are emerging treatments to rival salvage prostatectomy. 
– Salvage radiotherapy can benefit men with local relapse after RP but 
choosing which men will actually be cured by this approach and how it 
compares to adjuvant RT with or without concurrent ADT is still under 
investigation. 
Systemic therapy in recurrent prostate cancer 
- Recent evidence suggests that immediate ADT may be superior to delayed 
treatment but further trials to look specifically at this group of patients are 
needed.  
- A paradigm shift with regards to the use of upfront docetaxel with ADT in 
those with metastatic disease has recently occurred. Patient presenting with 
relapse of previous disease were under-represented in the pivotal trials that 
showed this survival benefit.  
- There are now multiple treatments for metastatic CRPC that prolong survival 
such as docetaxel, carbazitaxel, enzalutamide, abiraterone, radium 223 and 
immunotherapy. The evidence for treatment of those with recurrent M0 CRPC 
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